-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network April 1 hearingincludes butylphthalide soft capsules stone medicine, Tasly CSDP Fujian and other 10 varieties were the focus of monitoring, the amount of more than 5 million monthly shipments will be treated to lower prices; otherwise A 59 varieties, including esomeprazole from AZ and rivaroxaban from Bayer, have been focused on.
Among them, AZ has a total of 7 varieties on the list (1 key monitoring, 6 key concerns), all of which are heavyweights on the market.
On March 30, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
In addition, the "Notice" clarified that the drugs that belonged to the first batch of key monitoring and key attention lists, except for being included in the second batch, are no longer subject to key monitoring and key attention.
According to industry insiders Shandong Fengqing analysis, Fujian is currently on the iceberg and under the iceberg.
On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
He suggested that the companies in these two annexes should be highly vigilant and try to find a way not to break through the constraints of the relevant clauses and try to be a little low-key.
For drugs included in the key monitoring list, if the monthly delivery amount exceeds 5 million yuan, the online price will be lowered from the following month, and the maximum sales price limit and the medical insurance payment standard will be adjusted accordingly .
The lowered online price will no longer be called back
The lowered online price will no longer be called back
The "Notice" made it clear that for the drugs included in the key monitoring list, the "yellow" mark will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If the monthly shipment amount exceeds 5 million yuan, the manufacturer will be instructed to follow the “Notice on Carrying out the Sunshine Procurement of Drugs Based on the Medical Insurance Payment and Settlement Price” (Fujian The Medical Insurance Office (2017) No.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
Production and distribution enterprises that fail to rectify or refuse to rectify the drug purchases included in the key monitoring list are subject to suspension of payment for related drugs, suspension of online connection, and cancellation of online connection, depending on the situation.
The medical insurance audit and supervision are strengthened for the drugs included in the key monitoring list management.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Focus on the abnormal purchase growth of drugs, relevant manufacturers need to make a statement
The "Notice" made it clear that for drugs included in the list of key concerns, the "blue" logo will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
Strengthen the attention to the audit of the drugs on the key concern list , and promptly remind the relevant doctors or medical institutions if there are signs of unreasonable use.
For the drugs included in the list of key concerns, if there are abnormal purchases and use situations and the rectification is not effective, they should be adjusted and included in the list of key monitoring drugs in time.
Medical Network April 1 hearing includes butylphthalide soft capsules stone medicine, Tasly CSDP Fujian and other 10 varieties were the focus of monitoring, the amount of more than 5 million monthly shipments will be treated to lower prices; otherwise A 59 varieties, including esomeprazole from AZ and rivaroxaban from Bayer, have been focused on.
Among them, AZ has a total of 7 varieties on the list (1 key monitoring, 6 key concerns), all of which are heavyweights on the market.
On March 30, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
In addition, the "Notice" clarified that the drugs that belonged to the first batch of key monitoring and key attention lists, except for being included in the second batch, are no longer subject to key monitoring and key attention.
According to industry insiders Shandong Fengqing analysis, Fujian is currently on the iceberg and under the iceberg.
On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
He suggested that the companies in these two annexes should be highly vigilant and try to find a way not to break through the constraints of the relevant clauses and try to be a little low-key.
For drugs included in the key monitoring list, if the monthly delivery amount exceeds 5 million yuan, the online price will be lowered from the following month, and the maximum sales price limit and the medical insurance payment standard will be adjusted accordingly .
The lowered online price will no longer be called back
The lowered online price will no longer be called back
The "Notice" made it clear that for the drugs included in the key monitoring list, the "yellow" mark will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If the monthly shipment amount exceeds 5 million yuan, the manufacturer will be instructed to follow the “Notice on Carrying out the Sunshine Procurement of Drugs Based on the Medical Insurance Payment and Settlement Price” (Fujian The Medical Insurance Office (2017) No.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
Production and distribution enterprises that fail to rectify or refuse to rectify the drug purchases included in the key monitoring list are subject to suspension of payment for related drugs, suspension of online connection, and cancellation of online connection, depending on the situation.
The medical insurance audit and supervision are strengthened for the drugs included in the key monitoring list management.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Focus on the abnormal purchase growth of drugs, relevant manufacturers need to make a statement
The "Notice" made it clear that for drugs included in the list of key concerns, the "blue" logo will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
Strengthen the attention to the audit of the drugs on the key concern list , and promptly remind the relevant doctors or medical institutions if there are signs of unreasonable use.
For the drugs included in the list of key concerns, if there are abnormal purchases and use situations and the rectification is not effective, they should be adjusted and included in the list of key monitoring drugs in time.
Medical Network April 1 hearing includes butylphthalide soft capsules stone medicine, Tasly CSDP Fujian and other 10 varieties were the focus of monitoring, the amount of more than 5 million monthly shipments will be treated to lower prices; otherwise A 59 varieties, including esomeprazole from AZ and rivaroxaban from Bayer, have been focused on.
Medical News, April 1st Among them, AZ has a total of 7 varieties on the list (1 key monitoring, 6 key concerns), all of which are heavyweights on the market.
On March 30, the Fujian Provincial Medical Insurance Bureau issued the "Notice on Announcement of the Second Batch of Medical Insurance Key Monitoring Drugs and List of Key Drugs".
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
Among them, 10 medical insurance drugs were monitored and 59 were monitored (see the attached table at the end of the article for details).
The two types of lists are subject to dynamic management, and in principle, they are adjusted every six months.
In addition, the "Notice" clarified that the drugs that belonged to the first batch of key monitoring and key attention lists, except for being included in the second batch, are no longer subject to key monitoring and key attention.
According to industry insiders Shandong Fengqing analysis, Fujian is currently on the iceberg and under the iceberg.
On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
Enterprise Enterprise Enterprisepharmnet. On the iceberg, in accordance with the requirements of the state and the province, carry out mass purchases.
Below the iceberg, companies are given early warnings.
If monitoring and watchlists are carried out, the company will not pay attention to them.
The next mass pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase will be the target of killing.
com.
cn/news/yyzb/" target="_blank"> Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
He suggested that the companies in these two annexes should be highly vigilant and try to find a way not to break through the constraints of the relevant clauses and try to be a little low-key.
For drugs included in the key monitoring list, if the monthly delivery amount exceeds 5 million yuan, the online price will be lowered from the following month, and the maximum sales price limit and the medical insurance payment standard will be adjusted accordingly .
The lowered online price will no longer be called back
Standard Standard StandardThe lowered online price will no longer be called back
The "Notice" made it clear that for the drugs included in the key monitoring list, the "yellow" mark will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If there is an abnormal situation in the procurement and use, the provincial pharmaceutical procurement center and the medical insurance department at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If the monthly shipment amount exceeds 5 million yuan, the manufacturer will be instructed to follow the “Notice on Carrying out the Sunshine Procurement of Drugs Based on the Medical Insurance Payment and Settlement Price” (Fujian The Medical Insurance Office (2017) No.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
16) stipulated that the online price should be lowered, and the maximum sales price limit and the medical insurance payment standard should be adjusted accordingly.
The lowered online price will no longer be called back.
Production and distribution enterprises that fail to rectify or refuse to rectify the drug purchases included in the key monitoring list are subject to suspension of payment for related drugs, suspension of online connection, and cancellation of online connection, depending on the situation.
The medical insurance audit and supervision are strengthened for the drugs included in the key monitoring list management.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Unreasonable use is found in the audit, and it is strictly handled in accordance with relevant regulations and medical service agreements.
Physicians and medical institutions with unreasonable drug use shall be interviewed, notified, and the right to suspend medical insurance prescriptions shall be handled.
Focus on the abnormal purchase growth of drugs, relevant manufacturers need to make a statement
The "Notice" made it clear that for drugs included in the list of key concerns, the "blue" logo will be marked on the provincial joint procurement platform for pharmaceutical equipment.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
Strengthen the attention to the audit of the drugs on the key concern list , and promptly remind the relevant doctors or medical institutions if there are signs of unreasonable use.
Medicine, medicine, medicine For the drugs included in the list of key concerns, if there are abnormal purchases and use situations and the rectification is not effective, they should be adjusted and included in the list of key monitoring drugs in time.
